Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release
PMR-EC-1206
Phase 2 small_molecule active
Quick answer
Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release for Prophylaxis of primary liver, kidney, heart, lung, and intestinal organ transplant rejection is a Phase 2 program (small_molecule) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Astellas Pharma GmbH
- Indication
- Prophylaxis of primary liver, kidney, heart, lung, and intestinal organ transplant rejection
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active